Skip to main content
Clinical Trials/NCT00782418
NCT00782418
Completed
Phase 1

A Randomized Clinical Trial to Study Glucose Dependent Insulin Secretion Methodologies in Healthy Lean Male Subjects

Merck Sharp & Dohme LLC0 sites27 target enrollmentSeptember 2008

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
The Methodology Assessment of Glucose Dependent Insulin Secretion
Sponsor
Merck Sharp & Dohme LLC
Enrollment
27
Primary Endpoint
Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

This study will compare graded glucose infusion (GGI) to the hyperglycemic clamp (HGC) for assessment of glucose-dependent insulin secretion (GDIS) using exenatide as a probe.

Registry
clinicaltrials.gov
Start Date
September 2008
End Date
March 2009
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject has a Body Mass Index (BMI) of less than or equal to 26 kg/m2 at screening
  • Subject is judged to be in good health
  • Subject has been a nonsmoker for at least 3 months
  • Subject is willing to avoid strenuous physical activity for the duration of the study

Exclusion Criteria

  • Subject has a history of high blood pressure requiring treatment
  • Subject has a history of diabetes or a family history of diabetes mellitus
  • Subject is unable to discontinue all prescription and non-prescription drugs for duration of study
  • Subject consumes more than 3 alcoholic beverages per day
  • Subject consumes more than 6 servings of caffeinated beverages per day (1 serving = 120mg caffeine)
  • Subject has had major surgery or has donated or loss 1 unit of blood within 4 weeks of screening
  • Subject has multiple and/or severe allergies to foods or drugs
  • Subject is a regular user of illegal drugs
  • Subject is unwilling or unable to consume the standardized meals during the study and/or is on a carbohydrate restricted diet

Outcomes

Primary Outcomes

Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose

Time Frame: Steady-state of HGC: 90 - 120 minutes post dose; highest glucose infusion rate of GGI: 120 - 160 minutes post dose

Comparison of Glucose Dependent Insulin Secretion (GDIS) measured after HGC at steady-state to GDIS measured after GGI at the highest glucose infusion rate. Insulin Secretion Rate (ISR)/ Blood Glucose (BG)

Change From Baseline in Insulin Concentration

Time Frame: Pre and Post glucose infusion

Change From Baseline in C-peptide Concentration

Time Frame: Pre and Post glucose infusion

Similar Trials